title: Etoposide quinone is a redox-dependent topoisomerase II poison.
abstract: Etoposide is a topoisomerase II poison that is used to treat a variety of human cancers. Unfortunately, 2-3% of patients treated with etoposide develop treatment-related leukemias characterized by 11q23 chromosomal rearrangements. The molecular basis for etoposide-induced leukemogenesis is not understood but is associated with enzyme-mediated DNA cleavage. Etoposide is metabolized by CYP3A4 to etoposide catechol, which can be further oxidized to etoposide quinone. A CYP3A4 variant is associated with a lower risk of etoposide-related leukemias, suggesting that etoposide metabolites may be involved in leukemogenesis. Although etoposide acts at the enzyme-DNA interface, several quinones poison topoisomerase II via redox-dependent protein adduction. The effects of etoposide quinone on topoisomerase IIα-mediated DNA cleavage have been examined previously. Although findings suggest that the activity of the quinone is slightly greater than that of etoposide, these studies were carried out in the presence of significant levels of reducing agents (which should reduce etoposide quinone to the catechol). Therefore, we examined the ability of etoposide quinone to poison human topoisomerase IIα in the absence of reducing agents. Under these conditions, etoposide quinone was ∼5-fold more active than etoposide at inducing enzyme-mediated DNA cleavage. Consistent with other redox-dependent poisons, etoposide quinone inactivated topoisomerase IIα when incubated with the protein prior to DNA and lost activity in the presence of dithiothreitol. Unlike etoposide, the quinone metabolite did not require ATP for maximal activity and induced a high ratio of double-stranded DNA breaks. Our results support the hypothesis that etoposide quinone contributes to etoposide-related leukemogenesis.
authors: Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy, Nashville, Tennessee 37204-3951, USA.
authors: David A
authors: DA
authors: Jacob
authors: Susan L
authors: SL
authors: Mercer
authors: Neil
authors: N
authors: Osheroff
authors: Joseph E
authors: JE
authors: Deweese
references: DNA Repair (Amst). 2006 Sep 8;5(9-10):1093-108
references: 16857431
references: Mol Pharmacol. 1998 Mar;53(3):422-8
references: 9495807
references: Biochemistry. 2007 Mar 13;46(10):2856-64
references: 17298034
references: Blood. 1994 May 15;83(10):2780-6
references: 8180374
references: J Biol Chem. 1998 Jul 10;273(28):17643-50
references: 9651360
references: Eur J Cancer. 1998 Sep;34(10):1514-21
references: 9893622
references: Biochemistry. 2008 Apr 15;47(15):4501-9
references: 18355043
references: Nucleic Acids Res. 2000 May 1;28(9):1947-54
references: 10756196
references: J Mass Spectrom. 2001 Jul;36(7):771-81
references: 11473400
references: Med Pediatr Oncol. 1994;23(2):86-98
references: 8202047
references: Curr Med Chem Anticancer Agents. 2005 Jul;5(4):363-72
references: 16101488
references: Chem Biol. 2010 May 28;17(5):421-33
references: 20534341
references: Chem Res Toxicol. 2005 Apr;18(4):761-70
references: 15833037
references: N Engl J Med. 2005 Apr 14;352(15):1529-38
references: 15829534
references: Biochem Pharmacol. 1988 Oct 1;37(19):3579-89
references: 2972290
references: Mol Cell Biol. 1997 Jul;17(7):4070-9
references: 9199342
references: Mol Pharmacol. 1999 Sep;56(3):494-506
references: 10462537
references: Blood. 1991 Aug 15;78(4):1147-8
references: 1651134
references: Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10937-42
references: 9380738
references: J Natl Cancer Inst. 1988 Dec 7;80(19):1526-33
references: 2848132
references: Trends Biochem Sci. 2000 Aug;25(8):392-7
references: 10916160
references: J Biol Chem. 2001 May 11;276(19):15990-5
references: 11278845
references: J Clin Oncol. 1999 Feb;17(2):569-77
references: 10080601
references: J Biol Chem. 1989 Mar 15;264(8):4412-6
references: 2538443
references: Biochemistry. 2006 Aug 22;45(33):10140-52
references: 16906772
references: J Biol Chem. 2003 Feb 28;278(9):7406-12
references: 12473657
references: Mol Pharmacol. 1994 Feb;45(2):352-8
references: 8114683
references: Chem Res Toxicol. 2007 Jun;20(6):975-81
references: 17516663
references: Nucleic Acids Res. 2009 Feb;37(3):738-48
references: 19042970
references: Biochem Biophys Res Commun. 1997 Aug 8;237(1):24-7
references: 9266822
references: Biochemistry. 2008 Apr 1;47(13):4129-40
references: 18318502
references: Chem Res Toxicol. 2008 Apr;21(4):936-43
references: 18293940
references: Nat Rev Cancer. 2009 May;9(5):338-50
references: 19377506
references: Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81
references: 9789061
references: Cancer Res. 2001 Nov 1;61(21):7777-84
references: 11691792
references: Biochemistry. 2004 Mar 30;43(12):3731-9
references: 15035644
references: J Med Chem. 1989 Jul;32(7):1418-20
references: 2738876
references: Eur J Cancer. 1997 May;33(6):978-9
references: 9291827
references: J Pharmacol Exp Ther. 1992 May;261(2):491-6
references: 1578365
references: Biochemistry. 2001 Mar 20;40(11):3316-23
references: 11258951
references: Biochemistry. 2005 Mar 15;44(10):3972-81
references: 15751973
references: J Chromatogr B Biomed Sci Appl. 1997 Dec 5;703(1-2):209-15
references: 9448078
references: Biochemistry. 2001 Feb 6;40(5):1159-70
references: 11170441
references: Biochemistry. 2007 Jul 17;46(28):8217-25
references: 17580961
references: Clin Cancer Res. 2004 May 1;10(9):2977-85
references: 15131033
references: Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20
references: 3006680
references: Leukemia. 1998 Mar;12(3):346-52
references: 9529129
references: Leukemia. 2005 Dec;19(12):2289-95
references: 16193084
references: Biochemistry. 1997 May 20;36(20):5934-9
references: 9166762
references: N Engl J Med. 1991 Dec 12;325(24):1682-7
references: 1944468
references: J Biol Chem. 1995 Jan 27;270(4):1913-20
references: 7829529
references: Biochemistry. 2004 Jun 15;43(23):7563-74
references: 15182198
references: Drug Metab Dispos. 2004 Sep;32(9):993-1000
references: 15319341